Truist Securities Maintains Buy on Treace Medical Concepts, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has maintained a Buy rating on Treace Medical Concepts (NASDAQ:TMCI) but has reduced the price target from $17 to $12.
November 10, 2023 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities reaffirmed a Buy rating on Treace Medical Concepts but lowered the price target from $17 to $12.
The reduction in the price target by Truist Securities, despite maintaining a Buy rating, could lead to a negative perception among investors, potentially causing short-term bearish sentiment for TMCI's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100